StockData
GeoVax Labs, Inc. logo

GeoVax Labs, Inc. (GOVX) stock

GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$1.71−0.33 (-16.42%)

Close on Nov 13, 2026Market cap $717.73KP/E –Yield –

GeoVax Labs r&d expenses

Research and development expenses are spending on new products and technology.

GeoVax Labs's R&D Expenses for the twelve months ending Sep 30, 2026 was $12.83M, down 43.6% year over year. For fiscal 2025 it was $18.12M, down 23.6% from the year before. Over ten years it grew 26.8% a year on average. The highest annual figure on record is $23.71M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$18.12M-23.6%
FY2024Dec 31, 2024$23.71M+14.4%
FY2023Dec 31, 2023$20.72M+127.1%
FY2022Dec 31, 2022$9.12M-41.3%
FY2021Dec 31, 2021$15.55M+536.3%
FY2020Dec 31, 2020$2.44M+27.9%
FY2019Dec 31, 2019$1.91M+1.7%
FY2018Dec 31, 2018$1.88M-6.9%
FY2017Dec 31, 2017$2.02M+2.4%
FY2016Dec 31, 2016$1.97M+16.4%
FY2015Dec 31, 2015$1.69M-6.6%
FY2014Dec 31, 2014$1.81M-37.8%
FY2013Dec 31, 2013$2.91M-4.2%
FY2012Dec 31, 2012$3.04M-28.8%
FY2011Dec 31, 2011$4.28M-10.8%
FY2010Dec 31, 2010$4.79M+17.8%
FY2009Dec 31, 2009$4.07M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$2.82M-44.1%
Q2 FY2026Jun 30, 2026$3.11M-34.2%
Q1 FY2026Mar 31, 2026$3.90M-27.1%
Q4 FY2025Dec 31, 2025$2.99M-60.6%
Q3 FY2025Sep 30, 2025$5.04M-31.9%
Q2 FY2025Jun 30, 2025$4.73M+10.6%
Q1 FY2025Mar 31, 2025$5.35M+21.0%
Q4 FY2024Dec 31, 2024$7.61M+22.0%
Q3 FY2024Sep 30, 2024$7.40M+6.5%
Q2 FY2024Jun 30, 2024$4.28M-9.4%
Q1 FY2024Mar 31, 2024$4.43M+57.0%
Q4 FY2023Dec 31, 2023$6.23M+65.6%
Q3 FY2023Sep 30, 2023$6.95M+155.3%
Q2 FY2023Jun 30, 2023$4.72M+261.1%
Q1 FY2023Mar 31, 2023$2.82M+111.9%
Q4 FY2022Dec 31, 2022$3.76M-70.8%
Q3 FY2022Sep 30, 2022$2.72M+122.3%
Q2 FY2022Jun 30, 2022$1.31M+57.0%
Q1 FY2022Mar 31, 2022$1.33M+120.7%
Q4 FY2021Dec 31, 2021$12.89M+1602.5%
Q3 FY2021Sep 30, 2021$1.22M+193.8%
Q2 FY2021Jun 30, 2021$832.84K+80.5%
Q1 FY2021Mar 31, 2021$602.78K-25.5%
Q4 FY2020Dec 31, 2020$757.35K+73.7%
Q3 FY2020Sep 30, 2020$416.76K-10.9%
Q2 FY2020Jun 30, 2020$461.42K+2.3%
Q1 FY2020Mar 31, 2020$808.94K+45.6%
Q4 FY2019Dec 31, 2019$436.10K-5.6%
Q3 FY2019Sep 30, 2019$467.67K-16.1%
Q2 FY2019Jun 30, 2019$451.23K+21.2%
Q1 FY2019Mar 31, 2019$555.72K+14.1%
Q4 FY2018Dec 31, 2018$461.76K+2.8%
Q3 FY2018Sep 30, 2018$557.70K+11.9%
Q2 FY2018Jun 30, 2018$372.20K-28.2%
Q1 FY2018Mar 31, 2018$486.99K-11.7%
Q4 FY2017Dec 31, 2017$449.26K-0.5%
Q3 FY2017Sep 30, 2017$498.20K–
Q2 FY2017Jun 30, 2017$518.10K–
Q1 FY2017Mar 31, 2017$551.80K–
Q4 FY2016Dec 31, 2016$451.34K–

More GeoVax Labs figures

See a number that looks wrong?